{"nctId":"NCT00295061","briefTitle":"Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults","startDateStruct":{"date":"2006-05"},"conditions":["Alpha 1-Antitrypsin Deficiency"],"count":24,"armGroups":[{"label":"1 Alpha-1 MP","type":"EXPERIMENTAL","interventionNames":["Drug: Alpha-1 MP"]},{"label":"2 Prolastin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: alpha-1 proteinase inhibitor (human)"]}],"interventions":[{"name":"Alpha-1 MP","otherNames":["Alpha-1 antitrypsin (AAT)","TAL6004"]},{"name":"alpha-1 proteinase inhibitor (human)","otherNames":["Alpha-1 antitrypsin (AAT)","BAY x 5747","BAY 10-5233","TAL-05-00007"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Documented diagnosis of congenital Alpha1-antitrypsin deficiency\n* Must be receiving augmentation therapy with plasma-derived (human) Alpha1-Proteinase Inhibitor (Prolastin速) for at least one month prior to study entry.\n* Signed written informed consent prior to initiation of any study related procedures\n\nExclusion Criteria:\n\n* Females who are pregnant, breast feeding, or if of child-bearing potential, unwilling to practice adequate contraception throughout the study\n* Use of systemic steroids within the 2 weeks prior to receiving study treatment (this does not include the use of inhaled steroids used on a routine or as needed basis).\n* Subjects who have had exacerbations of their disease within one month of trial entry.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Alpha-1 MP vs. Prolastin速 of Area Under the Curve (AUC) From Day 0 to Day 7","description":"The primary objective of this study was to demonstrate the pharmacokinetic comparability (geometric least square mean ratio of AUC between the Alpha-1 MP vs. Prolastin速, 90% confidence interval falls within 0.80-1.25, FDA Guidance as being \"bioequivalent\" between two treatments) of Alpha-1 MP to Prolastin速 in subjects with alpha-1-anti-trypsin (AAT) deficiency by comparing AUC from Day 0 to Day 7 of plasma Alpha1-PI measured by the functional activity (potency) assay. AUC from Day 0 to Day 7 was calculated at steady state at the end of the first and second 8-week treatment periods during the 16-week double-blind, crossover phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"155.9","spread":null},{"groupId":"OG001","value":"152.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":24},"commonTop":["Upper respiratory tract infection","Headache","Arthralgia"]}}}